The present invention is a novel blood or plasma panel with utility in assessing chronic liver disease severity in a point-of-care setting. The scoring system exhibits 97.2% correlation to previously assigned Child Pugh scores and does not require clinical assessment beyond laboratory testing.

The present invention provides a rapid, specific, user friendly and cost effective lateral flow immunoassay based apparatus, method and kit for the detection of FVIII:Ag and VWF:Ag from human plasma samples. The LFIA based method and kit of the present invention can be used for the diagnosis of newly undiagnosed patients with bleeding history, menorrhagia cases, gynecological complications, differential diagnosis of Hemophilia A and VWD, recovery of factors in the transfused patient etc.

Compositions and methods useful for point of care testing for hemophilia by measuring coagulation factor levels are provided.

Provided herein is a method of detecting or predicting a relapse of multiple sclerosis in an individual afflicted with a form of multiple sclerosis, comprising: (a) providing a blood sample of the individual; (b) testing the blood sample to determine a protein activity or protein level, wherein the protein is Factor VIII, von Willebrand factor, or Protein C; and (c) detecting or predicting a relapse of multiple sclerosis in the individual if the protein activity or protein level is elevated compared to the protein activity or protein level in an individual not afflicted with the form of multiple sclerosis and patients' own baseline values. Also provided herein is a method of treating an individual afflicted with multiple sclerosis, who is experiencing a relapse or predicted to experience a relapse, comprising treating the individual by administering a dose of a steroid or anti-coagulation compound effective to alleviate the symptom of multiple sclerosis.

The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated FIX protein in a test sample.

Various aspects of the invention relate to recombinant polypeptides that specifically bind human von Willebrand Factor. Such recombinant polypeptides typically include a modified extracellular domain of platelet glycoprotein Ibα that typically comprises at least one mutation selected from G233T, D235V, and K237V, and such recombinant polypeptides optionally include an oligomerization domain.

The present disclosure provides methods and compositions for diagnosing and treating subject having a bleeding disorder. The disclosed methods comprise contacting a sample, e.g., a blood or plasma sample obtained from the patient, with an activation mixture comprising an activated coagulation factor and a phospholipid mixture, wherein the activation mixture is dried onto a solid substrate. Also provided is a global hemostasis test based on the integration of clotting time (Ct) and pharmacokinetics data. The methods and compositions presented can be applied to point-of-care diagnostic systems.

Disclosed is a method for obtaining information on von Willebrand factor (VWF), comprising the following steps: denaturing, with urea, VWF contained in a biological sample; fluorescently labeling the denatured VWF using a capturing agent that comprises a fluorescent substance and binds to the denatured VWF; and obtaining information on the size of the fluorescently-labeled VWF by fluorescence correlation spectroscopy or fluorescence cross-correlation spectroscopy.

The disclosure provides a method for treating sickle cell disease with A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13). The disclosure provides a method for increasing ADAMTS13-mediated von Willebrand factor (VWF) cleavage in a subject suffering from sickle cell disease by administering ADAMTS13. The disclosure also provides a method of treating a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease by administering ADAMTS13 after the onset of the VOC. The disclosure also provides a method of preventing a VOC in a subject suffering from sickle cell disease by administering ADAMTS13 prior to the onset of the VOC. The disclosure also provides a method of determining the efficacy of a treatment for a VOC in a mouse model.

Disclosed is a method for acquiring information of a target polypeptide, comprising: acquiring a diffusion time of a fluorescently labeled target polypeptide and a diffusion time of each of a plurality of fluorescently labeled reference polypeptides by fluorescence correlation spectroscopy or fluorescence cross-correlation spectroscopy, and acquiring information on size of the fluorescently labeled target polypeptide from the diffusion time of the fluorescently labeled target polypeptide with reference to the diffusion times of the plurality of fluorescently labeled reference polypeptides, wherein information on size of each of the plurality of fluorescently labeled reference polypeptides is known, and the sizes of the plurality of reference polypeptides are different from each other.